Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00617279 · ClinicalTrials.gov registry record · Phase 4
GORE PROPATEN Vascular Graft vs. Disadvantaged Autologous Vein Graft
A Phase 4 study, sponsored by W.L.Gore & Associates.
- Terminated
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
NCT00617279 is a Phase 4 study that was terminated before completion, run by W.L.Gore & Associates. The registered enrollment target is 31 participants.
The verdict
NCT00617279, a Phase 4 study, was terminated before completion, sponsored by W.L.Gore & Associates.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
Study Summary
The primary patency of the GORE PROPATEN Vascular Graft is equivalent to or better than disadvantaged autologous vein graft in an infragenicular peripheral bypass application at 12 months.
Interventions
- DEVICE GORE PROPATEN Vascular Graft
- PROCEDURE Disadvantaged Autologous Vein Graft
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00617279
The ClinicalTrials.gov registry entry for NCT00617279 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is W.L.Gore & Associates, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GORE PROPATEN Vascular Graft is the first listed.
NCT00617279 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00617279 about?
NCT00617279 is a clinical study titled "GORE PROPATEN Vascular Graft vs. Disadvantaged Autologous Vein Graft". The primary patency of the GORE PROPATEN Vascular Graft is equivalent to or better than disadvantaged autologous vein graft in an infragenicular peripheral bypass application at 12 months.
What is the current status of trial NCT00617279?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2007-12. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00617279?
The interventions under investigation include: GORE PROPATEN Vascular Graft (DEVICE), Disadvantaged Autologous Vein Graft (PROCEDURE).
Who is sponsoring clinical trial NCT00617279?
This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.